AKT1 and acute lymphoblastic leukemia: In summary, only pan-PI3K inhibitors like PIK-90 and GDC0941 and selective PI3Kγ inhibitors like AS-605 and AS-2524 effectively reduce baseline and cytokine-induced PI3K-Akt signals in T-ALL cell lines.